A
AXSOME THERAPEUTICS INC
NASDAQ: AXSM (Axsome Therapeutics, Inc.)
Kemas kini terakhir: 16 jam lalu156.35
-7.91 (-4.82%)
| Penutupan Terdahulu | 164.27 |
| Buka | 163.89 |
| Jumlah Dagangan | 680,802 |
| Purata Dagangan (3B) | 683,796 |
| Modal Pasaran | 7,997,816,832 |
| Harga / Pendapatan (P/E Ke hadapan) | 333.33 |
| Harga / Jualan (P/S) | 12.22 |
| Harga / Buku (P/B) | 90.88 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 May 2026 |
| Margin Keuntungan | -64.39% |
| Margin Operasi (TTM) | -45.67% |
| EPS Cair (TTM) | -5.76 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 62.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 397.02% |
| Nisbah Semasa (MRQ) | 2.03 |
| Aliran Tunai Operasi (OCF TTM) | -118.32 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -20.98 M |
| Pulangan Atas Aset (ROA TTM) | -26.17% |
| Pulangan Atas Ekuiti (ROE TTM) | -282.16% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Axsome Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
1.4
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.0 |
| Purata | 1.38 |
|
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 16.31% |
| % Dimiliki oleh Institusi | 76.41% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Deep Track Capital, Lp | 31 Dec 2025 | 1,150,000 |
| Rtw Investments, Lp | 31 Dec 2025 | 888,001 |
| Alethea Capital Management, Llc | 31 Dec 2025 | 668,710 |
| Eventide Asset Management, Llc | 31 Dec 2025 | 571,226 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 260.00 (HC Wainwright & Co., 66.29%) | Beli |
| Median | 223.00 (42.63%) | |
| Rendah | 202.00 (Wells Fargo, 29.20%) | Beli |
| Purata | 226.09 (44.61%) | |
| Jumlah | 10 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 175.12 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Guggenheim | 24 Feb 2026 | 220.00 (40.71%) | Beli | 169.95 |
| RBC Capital | 24 Feb 2026 | 222.00 (41.99%) | Beli | 169.95 |
| 21 Jan 2026 | 219.00 (40.07%) | Beli | 189.10 | |
| UBS | 24 Feb 2026 | 251.00 (60.54%) | Beli | 169.95 |
| 06 Jan 2026 | 248.00 (58.62%) | Beli | 171.88 | |
| Wells Fargo | 24 Feb 2026 | 202.00 (29.20%) | Beli | 169.95 |
| 13 Jan 2026 | 193.00 (23.44%) | Beli | 174.33 | |
| Wolfe Research | 24 Feb 2026 | 230.00 (47.11%) | Beli | 169.95 |
| Needham | 23 Feb 2026 | 225.00 (43.91%) | Beli | 174.76 |
| 31 Dec 2025 | 169.00 (8.09%) | Beli | 182.64 | |
| Jefferies | 03 Feb 2026 | 245.00 (56.70%) | Beli | 187.35 |
| Leerink Partners | 28 Jan 2026 | 205.00 (31.12%) | Beli | 185.17 |
| HC Wainwright & Co. | 20 Jan 2026 | 260.00 (66.29%) | Beli | 184.50 |
| 05 Jan 2026 | 200.00 (27.92%) | Beli | 171.49 | |
| Piper Sandler | 16 Jan 2026 | 223.00 (42.63%) | Beli | 177.27 |
| Morgan Stanley | 08 Jan 2026 | 204.00 (30.48%) | Pegang | 167.55 |
| Papar semua | ||||
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 27 Jan 2026 | Pengumuman | Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23 |
| 15 Jan 2026 | Pengumuman | Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia |
| 12 Jan 2026 | Pengumuman | Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue |
| 31 Dec 2025 | Pengumuman | Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer’s Disease Agitation |
| 31 Dec 2025 | Pengumuman | Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |